Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,464.21 46.68 0.32%
TOPIX 1,168.36 1.77 0.15%
HANG SENG 22,760.24 64.23 0.28%

Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market



   Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq
                                Capital Market

PR Newswire

JERUSALEM, February 7, 2013

JERUSALEM, February 7, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCQB: ORMPD), a developer of oral drug delivery
systems, announced today that NASDAQ has approved the company's application to
list its shares of common stock on the NASDAQ Capital Market. The company's
shares of common stock will begin trading on the Nasdaq Capital Market under
the symbol ORMP (formerly OTCQB: ORMPD) starting on Monday, February 11, 2013.

"Oramed is ready to begin trading on a higher profile exchange like NASDAQ,"
noted Nadav Kidron, CEO of Oramed. "We are very excited and believe that this
is the right marketplace for our shares. Listing on NASDAQ should enable us to
broaden our investor reach and increase visibility and liquidity of our
shares."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
approaching FDA-approved Phase 2 clinical trials, and with its oral exenatide
capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 1b/2a trials.
The company's corporate and R&D headquarters are based in Jerusalem.

Forward-looking statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss our listing on Nasdaq and how such listing would enable us to broaden
our investor reach and increase visibility and liquidity of our shares, or
when we discuss that our products are approaching FDA-approved Phase 2
clinical trials and Phase 1b/2a trials. These forward-looking statements are
based on the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection
for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required
to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely
develop and introduce new technologies, products and applications; lack of
validation of our technology as we progress further and lack of acceptance of
our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our process; greater
cost of final product than anticipated; loss of market share and pressure on
pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could cause the
actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Oramed undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:    Aviva Sherman
Oramed Pharmaceuticals
Cell: +972-54-792-4438
Office: +972-2-566-0001       
Email: aviva@oramed.com 

SOURCE Oramed Pharmaceuticals Inc.
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement